Abstract
Background: Infection of implanted medical devices has catastrophic consequences. For cardiac rhythm devices, pre-procedural cefazolin is standard prophylaxis but does not protect against methicillin-resistant gram-positive organisms, which are common pathogens in device infections. Objective: This study tested the clinical effectiveness of incremental perioperative antibiotics to reduce device infection. Methods: The authors performed a cluster randomized crossover trial with 4 randomly assigned 6-month periods, during which centers used either conventional or incremental periprocedural antibiotics for all cardiac implantable electronic device procedures as standard procedure. Conventional treatment was pre-procedural cefazolin infusion. Incremental treatment was pre-procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2-day post-procedural oral cephalexin. The primary outcome was 1-year hospitalization for device infection in the high-risk group, analyzed by hierarchical logistic regression modeling, adjusting for random cluster and cluster-period effects. Results: Device procedures were performed in 28 centers in 19,603 patients, of whom 12,842 were high risk. Infection occurred in 99 patients (1.03%) receiving conventional treatment, and in 78 (0.78%) receiving incremental treatment (odds ratio: 0.77; 95% confidence interval: 0.56 to 1.05; p = 0.10). In high-risk patients, hospitalization for infection occurred in 77 patients (1.23%) receiving conventional antibiotics and in 66 (1.01%) receiving incremental antibiotics (odds ratio: 0.82; 95% confidence interval: 0.59 to 1.15; p = 0.26). Subgroup analysis did not identify relevant patient or site characteristics with significant benefit from incremental therapy. Conclusions: The cluster crossover design efficiently tested clinical effectiveness of incremental antibiotics to reduce device infection. Device infection rates were low. The observed difference in infection rates was not statistically significant.
| Original language | English |
|---|---|
| Pages (from-to) | 3098-3109 |
| Number of pages | 12 |
| Journal | Journal of the American College of Cardiology |
| Volume | 72 |
| Issue number | 24 |
| DOIs | |
| Publication status | Published - 18 Dec 2018 |
| Externally published | Yes |
Keywords
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents/administration & dosage
- Antibiotic Prophylaxis/methods
- Arrhythmias, Cardiac/prevention & control
- Bacitracin/administration & dosage
- Cefazolin/administration & dosage
- Cluster Analysis
- Cross-Over Studies
- Defibrillators, Implantable/adverse effects
- Drug Administration Schedule
- Female
- Hospitalization
- Humans
- Logistic Models
- Male
- Middle Aged
- Pacemaker, Artificial/adverse effects
- Prosthesis-Related Infections/diagnosis
- Vancomycin/administration & dosage
Fingerprint
Dive into the research topics of 'Prevention of Arrhythmia Device Infection Trial: The PADIT Trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver